116 related articles for article (PubMed ID: 2826307)
1. Somatosensory-evoked potentials (SEPs) are affected differently by mu- and kappa-selective opioids in the dog.
Freye E; Buhl R; Schenk GK
Funct Neurol; 1987; 2(3):281-92. PubMed ID: 2826307
[TBL] [Abstract][Full Text] [Related]
2. Opioids with different affinity for subreceptors induce different effects on early and late sensory evoked potentials (SEP) in man.
Freye E; Buhl R; Ciaramelli F
NIDA Res Monogr; 1986; 75():551-4. PubMed ID: 2829001
[TBL] [Abstract][Full Text] [Related]
3. Bremazocine: an opiate that induces sedation and analgesia without respiratory depression.
Freye E; Hartung E; Schenk GK
Anesth Analg; 1983 May; 62(5):483-8. PubMed ID: 6301311
[TBL] [Abstract][Full Text] [Related]
4. Studies on the abstinence-like overshoot following reversal of the potent 19-isoamyl derivative of etorphine with naloxone. A comparison with the opioids fentanyl and alfentanil.
Freye E; Neruda B; Smith OW
Arzneimittelforschung; 1997 Jan; 47(1):6-9. PubMed ID: 9037435
[TBL] [Abstract][Full Text] [Related]
5. Discriminative stimulus effects of opioids in pigeons trained to discriminate fentanyl, bremazocine and water: evidence of pharmacological selectivity.
Picker MJ; Cook CD
Behav Pharmacol; 1997 Jun; 8(2-3):160-73. PubMed ID: 9833011
[TBL] [Abstract][Full Text] [Related]
6. Effect of mu- and kappa-opioid agonists on the electroconvulsive seizure threshold in mice and antagonism by naloxone and MR 2266.
Frey HH
Pharmacol Toxicol; 1988 Mar; 62(3):150-4. PubMed ID: 2836842
[TBL] [Abstract][Full Text] [Related]
7. [Somatosensory evoked potentials under alfentanyl].
Freye E; Segeth M; Hartung E
Anaesthesist; 1984 Feb; 33(2):103-7. PubMed ID: 6143516
[TBL] [Abstract][Full Text] [Related]
8. Further study of kappa opioids on increased urination.
Leander JD
J Pharmacol Exp Ther; 1983 Oct; 227(1):35-41. PubMed ID: 6137557
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the in vitro efficacy of mu, delta, kappa and ORL1 receptor agonists and non-selective opioid agonists in dog brain membranes.
Lester PA; Traynor JR
Brain Res; 2006 Feb; 1073-1074():290-6. PubMed ID: 16443205
[TBL] [Abstract][Full Text] [Related]
10. [Pharmacodynamic effects of S-(+)-ketamine on EEG, evoked potentials and respiration. A study in the awake dog].
Freye E; Latasch L; Schmidhammer H
Anaesthesist; 1992 Sep; 41(9):527-33. PubMed ID: 1416007
[TBL] [Abstract][Full Text] [Related]
11. Antinociceptive and respiratory effects of nalbuphine in rhesus monkeys.
Gerak LR; Butelman ER; Woods JH; France CP
J Pharmacol Exp Ther; 1994 Nov; 271(2):993-9. PubMed ID: 7965822
[TBL] [Abstract][Full Text] [Related]
12. Nalbuphine: an autoradiographic opioid receptor binding profile in the central nervous system of an agonist/antagonist analgesic.
De Souza EB; Schmidt WK; Kuhar MJ
J Pharmacol Exp Ther; 1988 Jan; 244(1):391-402. PubMed ID: 2826773
[TBL] [Abstract][Full Text] [Related]
13. Place-conditioning properties of mu, kappa, and sigma opioid agonists.
Iwamoto ET
Alcohol Drug Res; 1985-1986; 6(5):327-39. PubMed ID: 3011025
[TBL] [Abstract][Full Text] [Related]
14. [The opioid tramadol demonstrates excitatory properties of non-opioid character--a preclinical study using alfentanil as a comparison].
Freye E; Latasch L; Von Bredow G; Neruda B
Schmerz; 1998 Feb; 12(1):19-24. PubMed ID: 12799988
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular and respiratory effects of mu-, delta- and kappa-opiate agonists microinjected into the anterior hypothalamic brain area of awake rats.
Pfeiffer A; Feuerstein G; Kopin IJ; Faden AI
J Pharmacol Exp Ther; 1983 Jun; 225(3):735-41. PubMed ID: 6306217
[TBL] [Abstract][Full Text] [Related]
16. [Interaction of S-(+)-ketamine with opiate receptors. Effects on EEG, evoked potentials and respiration in awake dogs].
Freye E; Latasch L; Schmidhammer H; Portoghese P
Anaesthesist; 1994 Nov; 43 Suppl 2():S52-8. PubMed ID: 7840415
[TBL] [Abstract][Full Text] [Related]
17. In vivo binding of benzomorphans to mu, delta and kappa opioid receptors: comparison with urine output in the rat.
Richards ML; Sadée W
J Pharmacol Exp Ther; 1985 May; 233(2):425-32. PubMed ID: 2987482
[TBL] [Abstract][Full Text] [Related]
18. [Tifluadom, a benzodiazepine with opioid-like activity: study of its central mechanism of action in conscious dogs].
Schaal M; Freye E; Windelschmidt R
EEG EMG Z Elektroenzephalogr Elektromyogr Verwandte Geb; 1986 Mar; 17(1):27-31. PubMed ID: 3084201
[TBL] [Abstract][Full Text] [Related]
19. Antagonism of the analgesic effects of mu and kappa opioid agonists in the squirrel monkey.
Dykstra LA; Massie CA
J Pharmacol Exp Ther; 1988 Sep; 246(3):813-21. PubMed ID: 2843630
[TBL] [Abstract][Full Text] [Related]
20. Tifluadom (KC 5103) induces suppression and latency changes on somatosensory evoked potentials which are reversed by opioid antagonists.
Freye E; Hartung E; Schenk GK
Life Sci; 1983; 33 Suppl 1():537-40. PubMed ID: 6319908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
